Staging is the process of learning how much cancer is in your body, where it is, and if it has spread. Tests like digital rectal exams, biopsies using an anoscope, CTs and MRIs are done to help stage anal cancer. Your providers need to know about your cancer and your health so that they can plan the best treatment for you.
Staging of anal cancer is based on:
The staging system for anal cancer is called the “TNM system,” as described by the American Joint Committee on Cancer. It has three parts:
Your healthcare provider will use the results of the tests you had to determine your TNM result and combine these to get a stage from I (one) to IV (four).
Staging is important because it helps to guide your treatment plan. The staging system is very complex. Below is a summary of the staging system. Talk to your provider about the stage of your cancer.
Treatment for anal cancer is based on your health, your goals, the size of the tumor, and if it has spread to the lymph nodes or other organs. There can be more than one type of treatment used to treat anal cancer. Some of the treatments used are:
Often, chemotherapy and radiation are used together to treat anal cancer. This is called chemoradiation.
Radiation is the use of high-energy x-rays to kill cancer cells. Radiation may be the only treatment for earlier-stage anal cancers or used in combination with chemotherapy. (chemoradiotherapy).
Chemotherapy is the use of anti-cancer medicines that go through your whole body. These medicines may be given through a vein (IV, intravenously) or by mouth. Chemotherapy in anal cancer can be used with radiation therapy or as the only treatment, depending on the stage of your cancer.
The chemotherapy medications used to treat anal cancer include 5-FU, mitomycin, capecitabine, cisplatin, paclitaxel, oxaliplatin, leucovorin, and docetaxel. These may be used in combination and you may be given more than one medication, which is called a regimen.
Two newer medications, nivolumab and pembrolizumab, are also being used to treat anal cancer. These medications are called monoclonal antibodies. They work to stimulate the immune system to destroy cancer cells. These may be used in patients with metastatic disease or those whose cancer has progressed after their first treatments.
Surgery is not often used to treat anal cancer. It may be used in an early stage, superficial cancer, also called perianal cancer. The surgery to remove the tumor is called a local excision.
If you have advanced anal cancer or cancer that has come back after treatment or has not responded to treatment, your provider may recommend an abdominal perineal resection (APR). In this surgery, the anus is cut, including the anal muscles, and a permanent colostomy to collect stool is placed.
You may be offered a clinical trial as part of your treatment plan. To find out more about current clinical trials, visit the OncoLink Clinical Trials Matching Service.
Your care team will make sure you are part of choosing your treatment plan. This can be overwhelming as you may be given a few options to choose from. It feels like an emergency, but you can take a few weeks to meet with different providers and think about your options and what is best for you. This is a personal decision. Friends and family can help you talk through the options and the pros and cons of each, but they cannot make the decision for you. You need to be comfortable with your decision – this will help you move on to the next steps. If you ever have any questions or concerns, be sure to call your team.
You can learn more about anal cancer at OncoLink.org.
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.
Information Provided By: www.oncolink.org | © 2025 Trustees of The University of Pennsylvania